Open Access

REVIEW

Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine

Cord J. Peters¹, Clesson E. Turner², Gregory T. Chesnut^3,4, Veda N. Giri^5,6, Leonard G. Gomella⁵, Craig D. Shriver^3,7, Albert Dobi³

1 F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
2 Department of Pediatrics, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
3 Center for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland, USA
4 Urology Service, Department of Surgery, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland, USA
5 Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
6 Cancer Risk Assessment and Clinical Cancer Genetics, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
7 John P. Murtha Cancer Center Research Program, Department of Surgery, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland, USA
Address correspondence to Dr. Albert Dobi, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, 4301 Jones Bridge Rd, Bethesda, Maryland 20814 USA

Canadian Journal of Urology 2021, 28(3), 10659-10667.

Abstract

Introduction: The objective of our review is to summarize the 2019 Philadelphia Prostate Cancer Genetic Consensus recommendations and discuss their implications to the US Military Health System.
Materials and methods: Literature review.
Results: Our fighting force and retired service members will significantly benefit from the Philadelphia Prostate Cancer Genetic Consensus recommendations. Moreover, the experience of the equal access US Military Health System may help advancing genetic testing for cancer at national levels.
Conclusions: Priorities recommended by the 2019 Consensus for more research on genetic predisposition to prostate cancer in racially diverse populations is a promising step. The US Military Health System has the ability to provide equal access to implement advanced germline testing for its racially diverse population.

---

Keywords

---